Abstract: Described herein are phenoxy-pyridyl-pyrimidine compounds with inositol requiring enzyme 1 (IRE1) modulation activity or function having the Formula I structure or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such IRE1 modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

Abstract: A wet wipe that exhibits a novel combination of properties and methods for making such wet wipes are provided.

Abstract: The disclosure herein describes an emotional insight management system that provides user-configured prompts and insights to the user. In some examples, an insights application provides personalized, recurring prompts to encourage users to provide current emotional state updates to a well-being journal. The user's responses over time are aggregated within a historical trends report, which provides emotional response data over time. The insights application generates insights into potential reasons for the user's emotional states on a given day. The system analyzes the user-provided emotion response data with integrated work-related data to identify reasons for the user's mood and make recommendations for actions to be taken by users to reduce stress and improve the user's emotional well-being.

Abstract: An apparatus with one or more force plates senses of center-of-pressure and force-angle in the sagittal plane for a standing individual to provide an indication of balance capability based on the deduced functional relationship between center-of-pressure and force-angle within a limited band of frequencies. In one embodiment this relationship may be expressed as an intersection point of the force vectors with respect to the individual's center-of-mass.

Abstract: Disclosed is the use of a composite for extracting one or more metal or contaminating chemical species from an aerial or aqueous medium by selective binding, the composite including at least one porous template functionalized by at least one polymer, the polymer including one of the following chemical functions: primary, secondary or tertiary amine, amide, nitrile, pyridine, pyrole, thiol, thiolether, thiophene, thiadiazole, alcohol/hydroxyl, phenol, catechol, pyragalol, carboxylic acid, aldehyde, ester, acyl, crown ether, phosphate, phosphoryl, epoxide, halogen, haloalkane.

Abstract: A method and an integrated system for dyeing synthetic, natural, and blended textiles in the form of fabrics, yarns, and garments are provided. The integrated system includes a first pressurizing pump for pressurizing liquefied CO2 to supercritical CO2 (Sc—CO2); a second pressurizing pump for pressurizing CO2 to liquefied CO2; a liquefied CO2 storage vessel for storing the liquefied CO2 and the separated liquefied CO2 from the one or more cyclone separators; a heater for heating the Sc—CO2; a dyestuff vessel for mixing a dyestuff and the Sc—CO2 to obtain Sc—CO2-mixed dyestuff; a dyeing vessel for dyeing the textile by circulating the Sc—CO2 and the Sc—CO2-mixed dyestuff between the dyeing vessel and the dyestuff vessel; and one or more cyclone separators for removing the dyestuff from the Sc—CO2-mixed dyestuff to obtain separated liquefied CO2.

Abstract: Described herein are phenoxy-pyridazinyl-pyrimidine or phenoxy-pyrimidinyl-pyrimidine compounds and pharmaceutically acceptable salts thereof for use in the treatment of Ire1-mediated diseases and cancer.

Abstract: The invention is concerned with the compounds of formula (I) and formula (II): and pharmaceutically acceptable salts thereof. In addition, the present invention relates to methods of using the compounds of formula (I) and formula (II) as well as pharmaceutical compositions containing such compounds. The compounds are useful in treating diseases and conditions mediated by TEAD, such as cancer.

Abstract: Compounds of formula I: or pharmaceutical salts thereof, wherein m, n, p, q A, B, R1, R2, R3, R4, R5, R6 and R7 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.

Abstract: Described herein are pyrimidinyl-pyridyloxy-naphthyl compounds with inositol requiring enzyme 1 (IRE1) modulation activity or function having the Formula I or I? structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I or I? compounds, as well as methods of using such IRE1 modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

Abstract: The present invention concerns the identification of inhibitors of ubiquitin specific protease 7 (USP7), and methods of use thereof.

Abstract: Disclosed is a composite for extracting one or more metal or contaminating chemical species from an aerial or aqueous medium by selective binding, the composite including at least one porous template functionalized by at least one polymer, the polymer including one of the folowing chemical functions: primary, secondary or tertiary amine, amide, nitrile, pyridine, pyrole, thiol, thiolether, thiophene, thiadiazole, alcohol/hydroxyl, phenol, catechol, pyragalol, carboxylic acid, aldehyde, ester, acyl, crown ether, phosphate, phosphoryl, epoxide, halogen, haloalkane.

Abstract: Pyrazole carboxamide compounds of Formula I are provided, with various substituents, and including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk, and for treating cancer and immune disorders such as inflammation mediated by Btk. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

Abstract: A workflow management system provides a GUI Configurability tool that allows an end user to configure the system's workflow screens, workflow logic and data fields without the need to rewrite any programs. The system allows each workflow screen to represent and assist each individual task within a business process that may be defined and illustrated by a flowchart. The workflow screens work in conjunction with workflow logic to create an accurate one-to-one mapping of the individual tasks and decision logic within a business process flowchart. The system provides published interfaces that allow the use of third party hardware and software within workflows. The system also provides published interfaces to integrate extensible code that perform custom functions within the system.

Abstract: The present invention refers to a composition comprising a viral protein or fragment thereof, wherein the viral protein or fragment thereof is enclosed within a self-assembling protein nanocapsule, preferably ferritin, and wherein the viral protein, or fragment thereof is selected from a virus of the Togaviridae family. The viral protein or fragment thereof may also further be selected from a virus of the alphavirus subfamily.

Abstract: Compounds of formula I: or pharmaceutical salts thereof, wherein m, n, p, q A, B, R1, R2, R3, R4, R5, R6 and R7 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.

Abstract: The present invention concerns the identification of inhibitors of ubiquitin specific protease 7 (USP7), and methods of use thereof.

Abstract: Pyrazole carboxamide compounds of Formula I are provided, with various substituents, and including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk, and for treating cancer and immune disorders such as inflammation mediated by Btk. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

Abstract: A walking training device provides substantial fixation of the user's feet against a movable footplate in the direction of the user's stride while allowing toe lift and heel lift necessary for natural walking. The harness system provides an approximation of a shallow crossed four-bar linkage to provide angulation without substantial translation.

Abstract: Described herein are pyrimidinyl-pyridyloxy-naphthyl compounds with inositol requiring enzyme 1 (IRE1) modulation activity or function having the Formula I or I? structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I or I? compounds, as well as methods of using such IRE1 modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.